Lipigon Pharmaceuticals AB (publ) (STO:LPGO)
Sweden · Delayed Price · Currency is SEK 0.1790
-0.0040 (-2.19%)
Aug 6, 2025, 5:15 PM CET
Lipigon Pharmaceuticals AB Company Description
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden.
The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome.
Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia.
The company was incorporated in 2010 and is based in Umeå, Sweden.
Lipigon Pharmaceuticals AB (publ)
| Country | Sweden |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stefan Nilsson |
Contact Details
Address: TvistevAegen 48 C Umeå, 90736 Sweden | |
| Phone | 46 7 05 78 17 68 |
| Website | lipigon.se |
Stock Details
| Ticker Symbol | LPGO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015382072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stefan K. Nilsson | Co-Founder and Chief Executive Officer |
| Lars Öhman | Business Development Manager and Chairman |
| Hugo Petit | Chief Financial Officer |